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Hypertension is known to contribute to the progression of plaque formation in 
hyperlipidemia and is an important risk factor in cerebral atherosclerosis and 
stroke. This study presents an expression profile of various genes that are 
involved and regulated in hypertension in both intra- and extracranial vessels. 
The expression of genes and extension of damage to cerebral arteries caused by 
hypertension were evaluated quantitatively and morphologically in 10 New 
Zealand White rabbits with and without hypertension, induced using the 2-
kidney, 1-clip Goldblatt hypertension model.  Genes in the frontal cortex and 
middle cerebral artery respectively were filtered from microarray analysis and 
subjected to the Ingenuity Pathway Analysis where canonical pathways and a 
network of other genes related to our gene input were generated. From the 
selection of our genes of interest, 8 genes PPARA, PRL-R, PTGDR, P450, Gab3, 
Tnfs14, Sell and Lass3 were verified by RT-PCR.These genes have shown to be 
involved in the progression or contribution towards inflammatory diseases such 
as atherosclerosis. PPARA is a major regulator of lipid metabolism. Gab3 and 
Tnfs14 produce cytokines and chemokines while P450 protein is known to 
increase metabolism of arachidonic acid, a precusor in the production of 
eicosanoids which involves PTGDR. In addition, Tnfs14 and Sell are involved in 
endothelial cell adhesion, activation and disruption. Endothelial dysfunction is a 
hallmark for vascular diseases, and is often regarded as a key early event in the 
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development of atherosclerosis thus further study of these genes may lead to a 
better understanding on the role of hypertension in stroke. 
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1K1C one kidney one clip 
2K1C two kidney one clip 
ASTN2 adaptor-related protein complex 1, astrotactin 2 
CACNA1B calcium channel, voltage-dependent, N type, alpha 1B subunit 
CALB1 thrombin, cerebellar calbindin 
CBF cerebral blood flow 
CRB1 crumbs homolog 1 (Drosophila) 
CYP1A2 Cytochrome P450 1A2 
DNASE1L3 deoxyribonuclease I-like 3 
FAM167A family with sequence similarity 167, member A 
FOXN1  forkhead box N1 
Gab3 Growth factor receptor bound protein 2-associated protein 3 
GCLC glutamate-cysteine ligase 
HTN Hypertension 
ICA internal carotid artery 
IPA Ingenuity Pathway Analysis 
LASS3 LAG1 homolog, ceramide synthase 3 
MCA middle cerebral artery 
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MMP1 Interstitial collagenase Precursor 
NZW New Zealand wild type 
ODZ4 odd Oz/ten-m homolog 4  
PCGEM parametric test based on cross gene error model 
PCR Polymerase chain reaction 
PENK proenkephalin 
PPARA peroxisome proliferator-activated receptor alpha, partial 
Prlr prolactin receptor (partial) 
PTGDR Prostanoid DP receptor 
PVDF polyvinylidene difluoride 
PYY peptide YY 
SDS-PAGE sodium dodecyl sulphate polyacrylamide gel electrophoresis 
SELL L-selectin 
TAC1 neurokinin A  
TCRB T-cell receptor beta-chain V9, partial cds 
TNF tumor necrosis factor 
TNFSF14 tumor necrosis factor (ligand) superfamily, member 14 
TNFSF15 tumor necrosis factor (ligand) superfamily, member 15 































1. 1 Stroke 
Stroke has been defined by the World Health Organization (WHO) as “rapidly 
developing clinical signs of focal or global disturbance of cerebral function, with 
symptoms lasting 24 hours or longer or leading to death with no apparent cause 
other than of vascular origin” (Miller, 1999). Based on the analysis of American 
Heart Association, stroke becomes the leading cause of morbidity and mortality, 
especially in the elderly. Its incidence and prevalence increase sharply with age 
that 72% of the subjects suffering a stroke are over age 65. Many types of stroke 
are identified, such as ischemic stroke, intracerebral haemorrhage, subarachinoid 
haemorrhage and cerebral venous sinus thrombosis, but regardless of type, 
surviving a stroke could have devastating impact that the patients can experience 
loss of vision, speech, paralysis and confusion, physical and mental disabilities, 
depending on the part of brain that is affected. Therefore stroke brings a 
substantial economical burden on individuals and society. 
As described by WHO, stroke is a problem of vascular origin (eg. hypertension). 
In addition, lifestyle such as smoking, high salt intake, and underlying heart 
disease, diabetes, hyperlipidemia, family history, prior stroke or transient 
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ischemic attack, blood clotting disorders have also been shown to be the risk 
factors of stroke. 
Among them, high blood pressure is one of the highest contributing risk factor 
accounting for 91% of stroke incidents followed by high level of cholesterol 
(78%) and smoking (77%). (Travis et al., 2003; Horst and Korf, 1997) 
Ischemic stroke is caused by transient or permanent reduction in cerebral blood 
flow (CBF), resulting in the deficiency of glucose and oxygen supply to the 
territory of the affected region (Barber et al, 2003; Zemke et al, 2004,). As 
ischemic stroke is by far the most common type of stroke, accounts for 70 to 
80% of total stroke incidences (Feigin et al, 2003), of which 60% are attributable 
to large artery ischemia, developing effective ischemic stroke therapies has been 
the main goal for many researchers. The effort of development has led to several 
important successes during the past decade, though many disappointing failures. 
 
1.2 Hypertension 
Hypertension (HTN) or high blood pressure is a cardiac chronic medical 
condition in which the systemic arterial blood pressure is elevated. Persistent 
hypertension is one of the risk factors for stroke, myocardial infarction, heart 
failure and arterial aneurysm, and is a leading cause of chronic kidney 
failure(Miksche et al, 1970; Ninomiya et al, 2011). Moderate elevation of arterial 
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blood pressure leads to shortened life expectancy. Dietary and lifestyle changes 
can benefit blood pressure control and decrease the risk of associated health 
complications, although drug treatment may prove necessary in patients for 
whom lifestyle changes prove ineffective or insufficient. 
The most prevalent hypertension type is essential hypertension, affecting 90–
95% of hypertensive patients (Carretero & Oparil 2000). The direct cause of 
essential hypertension is unknown but there are many factors such as sedentary 
lifestyle (Kyrou et al. 2006), stress and obesity (Wofford & Hall 2004) that may 
contribute to the risk. Another risk factor is an increased level of renin that is 
secreted by the kidney (Segura & Ruilope 2007). Hypertension also increases the 
hardening of arteries (Riccioni 2009), leading to heart disease, peripheral 
vascular disease (Singer & Kite 2008) and strokes (White 2009).   
Hypertension can cause significant adaptive changes in the cerebral circulation 
(Strandgaard & Paulson 1995). The role of hypertension, atherosclerosis, and 
inflammation of blood vessels as the leading causes of stroke have been well 
established (Ross 1993, Lawes et al. 2004). Both atherosclerosis and 
hypertension are two important pathological vascular processes that involve an 
altered vascular homeostasis characterized by endothelial dysfunction. 
Furthermore, prospective cohort studies have shown that the association between 
blood pressure and risk of stroke was continuous and log linear (Lewington et al. 
2002, 1995, Lawes et al. 2003). Although hypertension alone does not induce 
atherosclerosis, experimental studies of animals have shown to accelerate plaque 
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formation and progression (Hollander et al. 1993, Xu et al. 1991), where the 
extent and severity of cerebral atherosclerosis were significantly related to the 
severity of hypertension in one study and plaque formation was still significantly 
greater in a hypertensive group of animals despite marked lowering of serum 
cholesterol values in another study. 
What makes hypertension in particular such an aggressive target for treatment is 
that it is the  most important modifiable risk factor for ischemic stroke (Sacco et 
al. 1997). Many randomized clinical trials of antihypertensive drugs have 
demonstrated both a reduction of carotid intima-media thickness, a validated 
measure of subclinical atherosclerosis and predictor risk for clinical 
cardiovascular events, than a protection against clinical stroke events. Large 
body of evidences has shown that antihypertensive drugs exert important anti-
atherosclerotic effects in non-cerebral vessels, which depend to some extent on 
the degree of blood pressure lowering provided by these drugs(Riccioni 2009). 
However little is known about the biochemical and molecular features of the 
impact of hypertension in cerebral vessels.  
 
1.3 Middle Cerebral Artery 
The middle cerebral artery (MCA) is one of the three major paired arteries that 
supply blood to the cerebrum. The MCA arises from the internal carotid and 
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continues into the lateral sulcus where it then branches and projects to many 
parts of the lateral cerebral cortex (Zhao BQ et al, 2001). It also supplies blood 
to the anterior temporal lobes and the insular cortices. 
The left and right MCAs rise from trifurcations of the internal carotid arteries 
and thus are connected to the anterior cerebral arteries and the posterior  
ecommunicating arteries, which connect to the posterior cerebral arteries(Yanni 







Figure A, Outer surface of cerebral hemisphere, 
showing areas supplied by cerebral arteries.  
 
Figure B, The arterial circle and arteries of the brain. The 
middle cerebral arteries (top of figure) arise from the 
internal carotid arteries. 
(Figure A and B were both adopted from Rhcastilhos, Gray’s Anatomy,2007) 
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Middle cerebral artery stroke describes the sudden onset of focal neurologic 
deficit resulting from brain infarction or ischemia in the territory supplied by the 
middle cerebral artery (MCA). 
The MCA is by far the largest cerebral artery and is the vessel most commonly 
affected by cerebrovascular accident (CVA). The MCA supplies most of the 
outer convex brain surface, nearly all the basal ganglia, and the posterior and 
anterior internal capsules. Infarcts that occur within the vast distribution of this 
vessel lead to diverse neurologic sequelae. Understanding these neurologic 
deficits and their correlation to specific MCA territories has long been 
researched.  
Research has also focused on the correlation between specific neurologic deficits 
after MCA stroke and differing outcomes and prognoses (Brown et al, 2010). 
Such efforts are important in ascertaining who may benefit from emergent 
antithrombotic therapies. Furthermore, these research efforts may later allow 
physiatrists to target rehabilitative efforts more effectively in appropriately 
selected patients who may derive benefit.  
 
1.4 Frontal Cortex 
The frontal cortex is an area in the brain of mammals, located at the front of each 
cerebral hemisphere and positioned anterior to (in front of) the parietal lobe and 
superior and anterior to the temporal lobes. It is separated from the parietal lobe 
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by a space between tissues called the central sulcus, and from the temporal lobe 
by a deep fold called the lateral (Sylvian) sulcus (Chen ZZ et al, 2009). The 
precentral gyrus, forming the posterior border of the frontal lobe, contains the 
primary motor cortex, which controls voluntary movements of specific body 
parts. 
The frontal lobe contains most of the dopamine-sensitive neurons in the cerebral 
cortex. The dopamine system is associated with reward, attention, short-term 
memory tasks, planning, and motivation (Lamchak et al, 2002). Dopamine tends 
to limit and select sensory information arriving from the thalamus to the fore-
brain.  
 
1.5 Animal Model of Hypertension 
 Much of the understanding of the molecular mechanisms involved in the 
pathophysiology of the cardiovascular system has been gained from in vitro 
studies. Nevertheless, the role of specific gene products in cardiovascular 
homeostasis should also be clarified in intact animals. Molecular biology, in 
particular, genetically modified animals generated by transgenic technology, has 
been used for investigating the basic mechanism of gene regulation and creating 
models for  human diseases (Robbins et al, 1993).  
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 Small animal models including rats and mice are being used to study the effects 
of hypertension. The current standard animal model that is widely used in related 
studies is two kidney one clip (2K1C) model or one kidney one clip 
model(1K1C), which carries a new understanding of the mechanisms in the end-
organ damage so that could provide new avenues for prevention of 
cardiovascular events. Many studies have examined effects of hypertension in 
gene expression changes in tissues such as liver, but thus far little is known 
about changes in the intracranial vessels and brain.  
Since the original work of Goldblatt et al (Goldblatt, 1934), the 2K1C (two 
kidney one clip) and 1K1C (one kidney one clip) animal models have greatly 
contributed to our knowledge of cardiovascular diseases. In the 2K1C model, 
one renal artery is constricted to chronically reduce renal perfusion, and the other 
kidney remains untouched. In the 1K1C model, one kidney is removed, and the 








Figure C, Quick concept for the 
two kidneys, one clip model of 
renal hypertension (Adopted from 
Michael Hultström, Discussing 
kidney physiology, nephrology 
and science, with interludes for 
dogs, photography, judo, dogs 
and food, 2001) 
 
In both models, the earliest phase of hypertension is characterized by a rapid rise 
in plasma renin in response to low renal arterial pressure and by the consequent 
increase in circulating Ang II. However, the mechanisms of the chronic phase of 
hypertension differ between the two models. In the 2K1C model, hypertension is 
maintained by a continuously activated renin-angiotensin system because 
pressure diuresis of the contralateral normal kidney prevents hypervolemia. In 
contrast, volume retention by the single stenotic kidney of the 1K1C animal 
shuts off renin secretion, providing a model of low-renin, volume-dependent 
hypertension. Nevertheless, both models develop cardiovascular hypertrophy 
constriction (De Simone et al, 1993; Corbier A et al, 1994). 
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 Table A． Although hypertension is equally present in both models， the one-
kidney model demonstrates normal to low plasma renin activity low renin 
content in the kidney， and increased plasma volume； the two-kidney model 
demonstrates increased renin in the plasma and clipped kidney as well as 
reduced or absent renin in the unclipped kidney． The hypertension of the two-
kidney model can be normalized with an angiotensin II antagonist， however， 
the hypertension of the one-kidney model does not respond to such 





Animal models of ischemic stroke have usually failed to successfully transition 
into human clinical practice. This is especially the case with mouse and rat 
models which have been the most commonly used models but have never made a 
successful transition into human application (Donnan, 2008). Larger animals 
apparently are required, but the selection is limited by other factors including 
unfavorable anatomy. The rabbit model is the one exception to this and has been 
successful in tPA therapy development leading to tPA as the standard of care in 
human stroke. (Bednar et al, 1997; Hamilton et al, 1994; Hoyte 2004)However, 
most rabbit models show wide variability in the strokes thus limiting precision. 
They use relatively short survival of a few hours to two days while deaths and 
severe symptoms limit longer term studies (Reasoner et al, 1996; Maynard et al, 
1998; Jahan et al, 2008). 
Adult New Zealand rabbits are large enough to provide adequate arterial detail to 
mimic human anatomy. A modified technique (Culp et al, 2007; Caldwell et al, 
2008; Kirchhof et al, 2002) of angiographic selection of the internal carotid 
artery (ICA) through femoral artery access with subsequent single clot 
embolization allowed us to produce similar strokes in a series of rabbits with a 
low death rate. This allows the study of stroke location and its relation to 
neurological function deficits. And this is an important step towards refinement 
and further validation of the animal model and can lead to its future use in long 




1.6 Aim of the study 
This study aims to examine the effect of hypertension alone in cerebral vessels, 
largely in the middle cerebral artery and frontal cortex and provide an overview 
on the genes that are regulated even before the onset of atherosclerosis in brain 
that will eventually lead to stroke. Early recognition or detection of genes 
regulated in this process could thus be made potentially relevant in a clinical 
setting or for pharmaceutical intervention in future. 
The present study was carried out in NZW rabbits in view of the importance of 
hypertension in neurological disorders such as stroke and vascular dementia, 
gene expression changes implicated in hypertension and its downstream impact 
































2.1 Rabbits and treatment 
Ten male New Zealand White rabbits weighing between 2-2.5kg were fed 
normal rabbit diet pellet and water ad libitum. After an acclimatisation period of 
2 weeks, rabbits were divided into hypertension (2K1C) and control groups 
(2K1CC). Hypertension was produced by constricting the left renal artery with a 
silver clip 0f 0.6 mm internal diameter. In the 2K1CC group, sham surgery was 
performed on the left renal artery. The right kidney was not touched in both 
groups.  
Rabbits were anesthetized by ketamine (70mg/kg weight). The kidney was 
exposed through a small flank incision, externalized, and carefully maintained 
with an ophthalmic chalazion forceps. For clipping, the renal artery of the left 
kidney was individualized over a short segment by blunt dissection, and a clip 
was placed close to the aorta. The kidney was then gently pushed back into the 
retroperitoneal cavity. For right nephrectomy, two ligatures were passed around 
the renal vascular pedicle and ureter and were tied. The kidney was removed 
without the adrenal gland. The muscle layer was sutured, and the skin incision 
was closed with surgical staples. A sham procedure, which included the entire 
surgery with the exception of artery clipping, was applied in control. 
Mean arterial pressure (MAP) of the rabbit was measured via the central ear 
artery (Powerlab 4/30, ADInstruments, USA) and blood from both groups were 
collected at 0, 4, 10 and 12 weeks. Approximately 3ml of blood was withdrawn 
from the rabbit ear artery and collected into 6ml BD Vacutainer Serum Tubes 
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with Clot activator and silicone-coated interior (BD Franklin Lakes, NJ). Rabbits 
were deeply anaesthetized intra-muscularly with 0.2ml/kg ketamine/xylazine 
cocktail prior to blood drawing and euthanasia by intravenous injection of 1ml 
pentabarbitol (300mg/ml) at the end of 12 weeks. The brain was carefully 
removed and the middle cerebral artery (MCA), frontal cortex (FC) and 
hippocampus (HC) from the right brain was manually dissected and immersed in 
RNAlater® (Ambion, TX, USA), snap frozen in liquid nitrogen and stored in -
80oC till further analysis. The left brain, aorta, liver and kidneys were fixed in 
two changes of 4% paraformaldehyde and stored at 4oC till further analysis. All 
procedures performed were approved by the Institutional Animal Care and Use 
Committee of the National University of Singapore in accordance with the 
National Advisory Committee for Laboratory Animal Research Guidelines.  
 
2.2 Serum Cholesterol 
The Cholesterol/Cholesteryl Ester Quantitation Kit provides a simple method for 
sensitive quantification of free cholesterol, cholesteryl esters, or both by 
colorimetric or fluorometric methods. Majority of the cholesterol in blood is in 
the form of cholesteryl esters which can be hydrolyzed to cholesterol by 
cholesterol esterase. Cholesterol is then oxidized by cholesterol oxidase to yield 
H2O2which reacts with a sensitive cholesterol probe to produce color (λmax 
=570 nm) and fluorescence (Ex/Em = 535/587 nm). The assay detects total 
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cholesterol (cholesterol and cholesteryl esters) in the presence of cholesterol 
esterase or free cholesterol in the absence of cholesterol esterase in the reaction. 
Cholesteryl ester can be determined by subtracting the value of free cholesterol 
from the total (cholesterol plus cholesteryl esters). 
Whole blood was centrifuged at 1000 x g for 15 min and the serum was 
transferred to new vials and kept frozen in -80oC till further analysis. Serum 
cholesterol levels were measured by fluorometric assay (Ex/Em 535/587 nm) 
according to the standard cholesterol kit instructions (BioVision, Inc., SF, USA). 
Samples were ran in triplicates and were read with a microplate reader (Infinite® 
i-control, Tecan Trading AG, Switzerland). 
 
2.3 RNA extraction 
The RNA extraction procedure combines the selective binding properties of a 
silica-based membrane with the speed of microspin technology. Nucleic acids, 
either DNA or RNA, are adsorbed onto the silica-gel membrane in the presence 
of chaotropic salts, which remove water from hydrated molecules in solution. 
Polysaccharides and proteins do not adsorb and are removed. A specialized high-
salt buffer system allows upto 100 μg of RNA longer than 200 bases to bind to 
the silica membrane. 
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Biological samples are first lysed and homogenized in the presence of a highly 
denaturing guanidine-thiocyanate–containing buffer, which immediately 
inactivates RNases to ensure purification of intact RNA. Ethanol is added to 
provide appropriate binding conditions, and the sample is then applied to a spin 
column, where the total RNA binds to the membrane and contaminants are 
efficiently washed away. After a wash step, pure nucleic acids are eluted under 
low- or no-salt conditions in small volumes.  
Total RNA was extracted and isolated from MCA and FC using TRizol reagent 
(Invitrogen, CA, USA) according to the manufacturer's recommended protocol. 
The lysate was homogenized, then centrifuged for 30s at 14000g in a microfuge and 
the supernatant was mixed with 650 μl of 70 % ethanol to clear lysate. The sample 
was applied to an RNeasy mini spin column (silicagel membrane, maximum binding 
capacity is 100 μg of RNA longer than 200 bases) and spun for 30 sec at 14000g 
and then flow-through was discarded. The RNA bound to the membrane was 
washed with buffer RW1 and RPE sequentially. High-quality RNA was then eluted 
in 20 μl of RNase free water. The concentration and purity of the extracted RNA 
was evaluated spectrophotometrically at 260 and 280 nm (Biophotometer, 





2.4 cDNA Synthesis 
The extracted RNA was purified and reverse transcribed with the RNeasy® Mini 
Kit (Qiagen, Inc., CA, USA) and High-Capacity cDNA Reverse Transcription 
Kit (Applied Biosystems, CA, USA) respectively. Reaction conditions were 
25 °C for 10 min, 37 °C for 120 min and 85 °C for 5 s. cDNA thus obtained was 
then diluted in sterile water and stored at -20° C. 
. 
2.5 Microarray Analysis 
Labelled cRNA from purified MCA and FC mRNA of 2K1C and 2K1CC rabbits 
was hybridized to the 1-colour Agilent Rabbit Microarray (Agilent, G2519F-
020908), according to the manufacturer’s recommended protocol. 10ul of total 
RNA was submitted to Genomax Technologies, Singapore, where RNA quality 
was analyzed using an Agilent 2100 Bioanalyzer, and cRNA generated and 
labelled using the one-cycle target labelling method. cRNA generated from each 
sample was hybridized to a single array according to standard Agilent protocols. 
Data collected were exported into GeneSpring v11 (Agilent Technologies, CA, 
USA) software for analysis using parametric test based on cross gene error 
model (PCGEM). Unpaired t-test approach was used to identify differentially 




2.6 Pathway and network analyses 
     The gene sets were analyzed using the Ingenuity Pathways Analysis (IPA) 
(Ingenuity Systems, Mountain View, CA). The respective up- and down-
regulated DEGs from the treated and control samples containing gene identifiers 
and corresponding expression values was uploaded into IPA application. Each 
identifier mapped to its corresponding object in Ingenuity's Knowledge Base (p-
value> 0.05 cut-off of >4 or 10 fold change) was set to identify molecules whose 
expression was significantly differentially regulated. Canonical pathways 
analysis identified the pathways from the IPA library of canonical pathways that 
were most significant to the data set. The significance of the association between 
the data set and the canonical pathway was measured in 2 ways: 1) a ratio of the 
number of molecules from the data set that map to the pathway divided by the 
total number of molecules that map to the canonical pathway is displayed. 2) 
Fisher’s exact test was used to calculate a p-value determining the probability 
that the association between the genes in the dataset and the canonical pathway 








2.7 Real-Time PCR 
Real-time PCR amplification was performed on the 7500 Real time PCR system 
to validate the expression of common genes of interest between the MCA and 
FC using TaqMan® Universal PCR Master Mix and customised rabbit probes. 
The PCR conditions were initial incubation of 50 °C for 2 min and 95 °C for 
10 min followed by 40 cycles of 95 °C for 15 s and 60 °C for 1 min. All 
reactions were carried out in triplicate. The fold change for each gene expression 
in MCA and FC was analysed and calculated by using the 2-∆∆CT method as 
described by Livak and Schmittgen. Rabbit beta-actin (Oc03824857_g1) was 
used as housekeeping genes. Unavailable rabbit primers were designed based on 












Table B: gene selection for RT-PCR 
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(partial) Prlr 8.10    NW1(FC) 
peptide YY PYY 10.15    NW1(FC) 
L-selectin SELL 8.32   NW1(FC) 
Prostanoid DP 
receptor PTGDR 7.39   NW1(FC) 
tumor necrosis factor 
(ligand) superfamily, 
member 15 
TNFSF15 7.34   NW1(FC) 
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2.8 Western Blot 
Frontal cortex from NZW rabbits were used for this portion of the study. A 
portion of the FC was homogenized in 10 volumes of ice-cold lysis buffer 
(150 mM sodium chloride, 50 mM Tris–hydrochloride, 0.25 mM EDTA, 1% 
Triton X-100, 0.1% sodium orthovanadate, and 0.1% protease inhibitor cocktail, 
pH 7.4). After centrifugation at 10,000g for 10 min at 4°C, the supernatant was 
collected. The protein concentrations in the preparation were then measured 
using the Bio-Rad protein assay kit. The homogenates (20 μg) were resolved in 
10% SDS–polyacrylamide gels under reducing conditions and electrotransferred 
to a polyvinylidene difluoride (PVDF) membrane. Non-specific binding sites on 
the PVDF membrane were blocked by incubating with 5% non-fat milk in 0.1% 
Tween 20 TBS (TTBS) for 1 h. The PVDF membrane was then incubated 
overnight in polyclonal antibody to PTGDR, PPARA, PRL-R, P450, Gab3, 
Tnfs14, SELL and Lass3 in 3% bovine serum albumin in TBST (Table C). After 
washing with TBST, the membrane was incubated with horseradish peroxidase-
conjugated secondary anti-mouse or anti-goat (Pierce, Rockford, IL) for 1 h at 
room temperature. Immunoreactivity was visualized using a chemiluminescent 
substrate (Supersignal West Pico, Pierce, and Rockford, IL). Loading controls 
were carried out by incubating the blots at 50 °C for 30 min with stripping buffer 
(100 mM 2-mercaptoethanol, 2% SDS, and 62.5 mM Tris–hydrochloride, pH 
6.7), followed by reprobing with a mouse monoclonal antibody to β-actin 
(Sigma; diluted 1:10,000 in TBST) and horseradish peroxidase-conjugated anti-
mouse IgG (1:2,000 in TBST, Pierce). Exposed films containing blots were 
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scanned, and the densities of the bands were measured, using Gel-Pro Analyzer 
3.1 program (Media Cybernetics, Silver Spring, MD). The densities of the bands 
were normalized against those of β-actin, and the mean ratios were calculated. 
Possible significant differences between the values from the 2K1C rabbits and 
control rabbits were then analyzed, using Student’s t-test. P < 0.05 was 
considered significant 
 









Mouse monoclonal to 
LIGHT(ab57901) Abcam 1:200 1:2000 
Goat polyclonal to 
Cytochrome P450 
1A1+1A2 (ab4227) 
Abcam 1:100 1:2000 
PRL-R(B10):sc-74520 Santa Cruz 1:200 1:2000 
PPARA(C-20):sc-1982 Santa Cruz 1:200 1:2000 
Gab3(D-20):sc-22615 Santa Cruz 1:200 1:2000 
LASS3(T-17):sc-55962 Santa Cruz 1:200 1:2000 
DP(S-14):sc-55818 Santa Cruz 1:500 1:2000 



























3.1 Body Weight 
The average body weight between the two groups was not found to be 
significantly different (Figure 1A). At the end of 12 weeks, mean weight were 






















Fig 1. A) Weight chart of rabbits measured on alternate weeks during the study. 








 3.2 Serum Cholesterol and Mean Arterial Pressure 
No significant increase in total cholesterol was observed in the serum of 2K1C 
rabbits at 0, 4, 10 and 12 weeks compared to the normal fed rabbits (Figure 1B). 
Before initiation of the diet, the mean cholesterol level of treated rabbits was 
45.31mg/dl while control animals had a mean of 66.20mg/dl. However, after 12 
weeks of cholesterol feeding, the mean cholesterol level of treated rabbits 
increased to 67.82 while control animals were 55.19mg/dl.  

























Ctrl 66.20 69.79 78.08 55.19
HypT 45.31 44.43 60.08 67.82
1 2 3 4
 
Fig1. B) Serum cholesterol levels in rabbits measured at baseline, 4, 10 and 
12 weeks. Data are plotted as mean ± S.D. and analyzed by Student’s T-test. P 




The mean arterial pressure (MAP) at the different time points within the 2K1C 
group was significantly increased from baseline at 85mmHg, with a peak of 
166.5mmHg at 10 weeks. In comparison, the baseline of 2K1CC group was 
69.8mmHg and it increased to 106.4mmHg at 10 weeks (Figure 1C). 
 
Fig1.B) 

















Ctrl 69.83382 76.37 106.40952 97.91338
Hypt 85.03504 157.39536 166.509 157.3444
0 4 10 12
 
Fig1.C) Mean arterial pressure (MAP) levels in rabbits measured at baseline, 4, 
10 and 12 weeks. Data are plotted as mean ± S.D. and analyzed by Student’s T-
test. P < 0.05 indicates significant differences. Significant difference began from 




3.3 Microarray data collection and analysis 
The 2K1C and 2K1CC rabbits were sacrificed 12 weeks after the surgery was 
initiated and MCA and FC were harvested for microarray analysis. The gene 
expression profile on the FC and MCA of the 2K1C group was compared to the 
2K1CC group. A total of 10440 and 12106 genes were found for FC and MCA 
respectively. A total of 854 and 248 genes which had greater than 4-fold change 
were found in the FC and MCA respectively. Common genes were then 
identified between the two brain regions and a total of 195 genes with greater 
than 4-fold change were found (Fig 2). Of these, unknown and repeated genes 
were omitted and only up regulated genes with more than 7 fold change and 
down regulated genes with more than 4 fold changes in the FC and up- and down 
regulated genes with more than 6 fold changes in the MCA were analyzed.  The 
results were then classified using Ingenuity Pathway Analysis (IPA).  
 
Fig 2. Venn diagram summarizing genes with p>0.05 and fold change >4 
expressed in middle cerebral artery and frontal cortex. 
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3.3.1 Differentially expressed genes found in MCA 
There were a total of 29 up regulated DEGs (differential expressed genes) and 31 
down regulated DEGs identified in the MCA (Table 1, 2).  DEGs that were 
found up-regulated include family with sequence similarity 167, member A 
(FAM167A), substance P, neuropeptide gamma, neurokinin A (TAC1), thrombin, 
cerebellar calbindin (CALB1) and proenkephalin (PENK). Down regulated 
genes included forkhead box N1 (FOXN1), BRCA2 and CDKN1A interacting 
protein and secreted frizzled-related protein 4 (SFRP4). 
 
Table 1. Up Regulated genes in MCA with more than 6 fold change 
Gene Gene symbol 
Fold 
Change P-value 
family with sequence similarity 167, member A FAM167A 14.04 0.00000 
substance P, neuropeptide gamma, neurokinin A TAC1 13.08 0.01093 
LAG1 homolog, ceramide synthase 3 LASS3 11.44 0.00027 
thrombin mRNA THROMBIN 10.16 0.00145 
family with sequence similarity 53, member C Fam53c 9.87 0.00001 
cerebellar calbindin Calb1 8.96 0.00515 
proenkephalin PENK 8.73 0.01095 
Type II adenylyl cyclase Fragment 
LOC10000920
1 8.29 0.00001 
deoxyribonuclease I-like 3 DNASE1L3 8.27 0.01184 
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tubulin tyrosine ligase-like family, member 5 TTLL5 8.16 0.00004 
olfactory receptor, family 1, subfamily J, member 1 OR1J1 8.14 0.00006 
Interstitial collagenase Precursor (Matrix 
metalloproteinase-1)(MMP-1) MMP1 8.12 0.00047 
TAF15 RNA polymerase II, TATA box binding 
protein (TBP)-associated factor TAF15 7.45 0.00008 
Purkinje cell protein 4 PCP4 7.19 0.00438 
zinc finger, DHHC-type containing 23 ZDHHC23 7.18 0.00001 
odz, odd Oz/ten-m homolog 4 (Drosophila) ODZ4 7.16 0.00003 
ankyrin and armadillo repeat containing ANKAR 7.05 0.00003 
tyrosine hydroxylase mRNA, partial cds BDNF 6.88 0.00122 
stefin A2 mRNA, partial cds Stfa2 6.69 0.01085 
N(alpha)-acetyltransferase 25, NatB auxiliary 
subunit NAA25 6.43 0.00049 
corticotropin releasing hormone binding protein CRHBP 6.38 0.00009 
ankyrin repeat and SOCS box-containing 4 Asb4 6.36 0.00000 
solute carrier family 5 (sodium/glucose 
cotransporter), member 12 SLC5A12 6.34 0.00104 
Gonadotropin-releasing hormone receptor GNRHR 6.33 0.00003 
secretagogin, EF-hand calcium binding protein SCGN 6.28 0.01846 
Cytochrome P450 1A2 CYP1A2 6.15 0.00034 
KIAA0232 KIAA0232 6.13 0.00007 
Fanconi anemia, complementation group C FANCC 6.10 0.00005 
chromosome X open reading frame 57 CXorf57 6.07 0.03688 
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 Table 2. Down Regulated genes in MCA with more than 6 fold change 
Gene Gene symbol 
Fold 
Change P-value 
forkhead box N1 Foxn1 26.20 0.00529 
coiled-coil domain containing 55 CCDC55 24.13 0.00008 
BRCA2 and CDKN1A interacting protein CDKN1A 23.79 0.00001 
THUMP domain containing 3 THUMPD3 17.18 0.00002 
AT rich interactive domain 2 (ARID, RFX-like) Arid2 16.92 0.00002 
Probable methyltransferase C20orf7, mitochondrial 
Precursor C20orf7 15.92 0.00001 
ADAM metallopeptidase with thrombospondin type 1 
motif, 17 Adamts17 15.85 0.00010 
peptidylprolyl isomerase G (cyclophilin G) ppig 12.61 0.00007 
hematopoietic prostaglandin D synthase Hpgds 12.38 0.00612 
cyclin H CCNH 10.89 0.00002 
Lyrm7 homolog (mouse) LYRM7 10.41 0.00003 
male-specific lethal 2 homolog (Drosophila) MSL2 9.72 0.00082 
secreted frizzled-related protein 4 SFRP4 9.32 0.00001 
ankyrin 2, neuronal ANK2 9.32 0.00019 
Myosin heavy chain Fragment Mhc 9.27 0.00003 
Ras-related protein Rab-7a Rab7a 9.20 0.00013 
guanine deaminase GDA 8.64 0.03019 
NLR family, pyrin domain containing 5 NLRP5 8.60 0.00001 
membrane-spanning 4-domains, subfamily A, 
member 1 Ms4a2 7.86 0.00057 
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sorting nexin 9 SNX9 7.82 0.00101 
protein tyrosine phosphatase, non-receptor type 23 PTPN22 7.80 0.00123 
large subunit GTPase 1 homolog (S. cerevisiae) LSG1 7.69 0.00010 
coiled-coil domain containing 59 Ccdc59 7.66 0.00001 
ribosomal protein S12 RpS12 7.57 0.00364 
breast carcinoma amplified sequence 2 BCAS2 7.39 0.00027 
mitochondrial ribosomal protein L15 mRpL15 6.97 0.00000 
Transmembrane protein C3orf1 (Protein M5-14) C3orf1 6.72 0.00217 
olfactory receptor, family 4, subfamily D, member 2 OR1D2 6.61 0.00151 
tumor necrosis factor, alpha-induced protein 8 TNFAIP8 6.59 0.00194 
LIM domains containing 1 LIMCH1 6.10 0.00001 
Neurolysin, mitochondrial Precursor NLN 6.05 0.00332 















3.3.2 Differentially expressed genes found in FC 
There were a total of 36 up regulated DEGs and 13 down regulated DEGs identified in 
the FC (Table 3,4). DEGs that were up-regulated include Cytochrome P450 1A2 
(CYP1A2), odz, odd Oz/ten-m homolog 4 (ODZ4), peroxisome proliferator-activated 
receptor alpha, partial (PPARA), and tumor necrosis factor (TNF). Down regulated 
DEGs included calcium channel, voltage-dependent, N type, alpha 1B subunit 
(CACNA1B), glutamate-cysteine ligase (GCLC), adaptor-related protein complex 1, 
astrotactin 2 (ASTN2), sodium channel, voltage-gated, type III, alpha subunit (SCN3A), 













Table 3. Up Regulated genes in FC with more than 7 fold change 
Gene Gene symbol 
Fold 
Change P-value 
Cytochrome P450 1A2 CYP1A2 24.38 0.00009 
odz, odd Oz/ten-m homolog 4 (Drosophila) ODZ4 19.13 0.00063 
peroxisome proliferator-activated receptor alpha, 
partial PPARA 16.62 0.00003 
T-cell receptor beta-chain V9, partial cds TCRB 15.21 0.00008 
keratin 32 KRT32 12.35 0.00006 
olfactory receptor, family 1, subfamily J, member 1 OR1J1 11.56 0.00447 
transmembrane protease, serine 11A 
TMPRSS1
1A 11.41 0.03971 
leucine rich repeat containing 53 LRRC53 10.69 0.01634 
double homeobox A DUXA 10.41 0.00007 
crumbs homolog 1 (Drosophila) CRB1 10.29 0.00000 
Peptide YY PYY 10.15 0.00031 
transcription factor CP2-like 1 Tcfcp2l1 9.61 0.00050 
pre-alpha S2a casein CSN1S2A 9.37 0.03325 
CU464574 SSH library 4 cells embryo subtracted 
from morulae embryo  9.25 0.03452 
glycine receptor, alpha 1 GLRA1 9.18 0.04313 
haloacid dehalogenase-like hydrolase domain 
containing 3 HDHD3 9.16 0.01265 
tumor necrosis factor (ligand) superfamily, member 
14 TNFSF14 8.65 0.00005 
Rabbit K+  8.44 0.00142 
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Growth factor receptor bound protein 2-associated 
protein 3 Gab3 8.42 0.00039 
selectin L SELL 8.32 0.04840 
prolactin receptor Prlr 8.10 0.00272 
methyltransferase like 11B Mettl11b 8.03 0.00061 
Connexin 50 Fragment Gja8 7.93 0.00005 
T-cell receptor delta chain V2-D-J-C, partial cds  7.92 0.01044 
interleukin 9 Il9r 7.66 0.00026 
trans-2,3-enoyl-CoA reductase-like Tecrl 7.61 0.00104 
Alpha-3 type IV collagen Fragment Col4a3bp 7.55 0.04080 
PHD and ring finger domains 1 UHRF1 7.47 0.00713 
prostaglandin D2 receptor PTGDR 7.39 0.00169 
beta-carotene 15,15'-monooxygenase 1 BCMO1 7.39 0.00025 
protease, serine, 33 PRSS33 7.35 0.00002 
tumor necrosis factor (ligand) superfamily, member 
15 TNFSF15 7.34 0.00058 
peptidyl arginine deiminase, type IV  7.31 0.00342 
tumor necrosis factor TNF 7.16 0.00392 
purinergic receptor P2Y, G-protein coupled, 10 Padi4 7.08 0.01065 






 Table 4. Down Regulated genes in FC with more than 4 fold change  
 
 
Gene Gene symbol 
Fold 
Change P-value  
ubiquinol-cytochrome c reductase binding protein UQCRB 15.94 0.03329  
immunoglobulin superfamily, member 9 IGSF9 11.40 0.04205  
FGGY carbohydrate kinase domain containing FGGY 7.90 0.02627  
SEC24 family, member B (S. cerevisiae) SEC24B 6.21 0.04005  
REV1 homolog (S. cerevisiae) REV1 5.98 0.01982  
calcium channel, voltage-dependent, N type, alpha 
1B subunit (CACNA1B) Cacna1b 5.47 0.01625  
glutamate-cysteine ligase, catalytic subunit Gclc 5.38 0.02757  
DENN/MADD domain containing 5A Dennd5a 4.92 0.04442  
forkhead box F2 FOXF2 4.85 0.01935  
astrotactin 2 ASTN2 4.80 0.01031  
sodium channel, voltage-gated, type III, alpha subunit Scn3a 4.56 0.00422  
WD repeat domain 61 Wdr61 4.42 0.04084  
adaptor-related protein complex 1, sigma 2 subunit AP1S2 4.22 0.04349  







 3.3.3 Differentially expressed genes found in common 
There were 11 up regulated DEGs according to the highest fold changes of the 
FC and 8 up regulated DEGs according to the highest fold changes of the MCA 
(fold change >8) (Table 5a,b) that were found in common between the FC and 
MCA. These included CYP1A2, ODZ4, PPARA, CRB1 and MMP1, some of 
which are important genes found associated with AD, diabetes and CAD. There 
were 24 down regulated DEGs that were in common in both the FC and MCA 
(fold change >2) (Table 6) however not much is known about many of these 














 Table 5a. Up Regulated genes in common with more than 8 fold change (FC) 









Cytochrome P450 1A2 CYP1A2 6.09 0.00006 24.38 0.00009 
odz, odd Oz/ten-m homolog 
4 ODZ4 4.86 0.00042 19.13 0.00063 
peroxisome proliferator-
activated receptor alpha, 
partial  
PPARA 
3.00 0.02050 16.62 0.00003 
T-cell receptor beta-chain 
V9, partial cds TCRB 2.84 0.01261 15.21 0.00008 
olfactory receptor, family 1, 
subfamily J, member 1 OR1J1 5.27 0.00155 11.56 0.00447 
leucine rich repeat 
containing 53 LRRC53 2.38 0.00538 10.69 0.01634 
crumbs homolog 1 
(Drosophila) CRB1 3.73 0.00133 10.29 0.00000 
haloacid dehalogenase-like 
hydrolase domain containing 
3 HDHD3 3.82 0.00021 9.16 0.01265 




4 2.52 0.01107 8.65 0.00005 
Oryctolagus cuniculus K+  4.23 0.00000 8.44 0.00142 
Growth factor receptor 
bound protein 2-associated 
protein 3 Gab3 2.28 0.00361 8.42 0.00039 
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 Table 5b. Up Regulated genes in common with more than 8 fold change (MCA) 









family with sequence 
similarity 167, member A FAM167A 14.04 0.00000 6.68 0.00092 
LAG1 homolog, ceramide 
synthase 3 LASS3 11.44 0.00027 5.16 0.00151 
family with sequence 
similarity 53, member C Fam53c 9.87 0.00001 4.54 0.00049 
Type II adenylyl cyclase 
Fragment 
LOC100009
201 8.29 0.00001 4.27 0.00001 
deoxyribonuclease I-like 
3 DNASE1L3 8.27 0.01184 2.72 0.02320 
tubulin tyrosine ligase-
like family, member 5 TTLL5 8.16 0.00004 3.96 0.00020 
olfactory receptor, family 
1, subfamily J, member 1 OR1J1 8.14 0.00006 6.75 0.00540 
Interstitial collagenase 
Precursor MMP1 8.12 0.00047 2.90 0.00021 










Table 6. Down Regulated genes in common with more than 2 fold change 










member 9 IGSF9 2.79 0.04124 11.40 0.04205 
REV1 homolog (S. cerevisiae) REV1 4.14 0.04045 5.98 0.01982 
delta-like 4 (Drosophila) DLL4 2.50 0.03809 3.60 0.02787 
beta tropomyosin TPM2 2.30 0.00462 3.41 0.00358 
cell division cycle 27 homolog 
(S. cerevisiae)  CDC27 2.46 0.01430 3.31 0.00096 
RNA pseudouridylate synthase 
domain containing 4 RPUSD4 4.11 0.00095 3.23 0.02484 
kinesin family member 20A KIF20A 2.21 0.00620 2.83 0.03375 
LIM domains containing 1 LIMCH1 6.10 0.00001 2.83 0.01483 
OTU domain containing 6A OTUD6A 3.59 0.00030 2.64 0.00718 
polymerase (DNA directed), 
alpha 1, catalytic subunit POLA1 2.23 0.01108 2.61 0.01035 
potassium intermediate/small 
conductance calcium-activated 
channel, subfamily N, member 
2 KCNN2 2.01 0.01518 2.61 0.01391 
StAR-related lipid transfer 
(START) domain  STARD5 2.40 0.00092 2.54 0.03710 
RNA pseudouridylate synthase 
domain containing 4 RPUSD4 2.88 0.03351 2.50 0.02324 
calcium binding and coiled-coil 
domain 2 CALCOCO2 2.52 0.00287 2.47 0.00946 
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guanylate cyclase 1, soluble, 3 GUCY1B3 2.52 0.00344 2.47 0.01127 
Glycine N-methyltransferase 
Fragment GNMT 4.17 0.00037 2.40 0.04815 
transmembrane protein 59 TMEM59L 3.42 0.02361 2.36 0.01426 
sperm specific antigen 2 SSFA2 2.57 0.00124 2.33 0.01040 
dual specificity phosphatase 1 Dusp1 2.79 0.02360 2.31 0.02954 
family with sequence similarity 
177, member A1 FAM177A1 4.41 0.00000 2.27 0.04698 
tetraspanin 12 TSPAN12 2.09 0.04706 2.25 0.00411 
cell division cycle 37 homolog 
(S. cerevisiae)-like 1 CDC7 2.44 0.00358 2.22 0.03243 
Transmembrane protein C3orf1 
(Protein M5-14) C3orf1 6.72 0.00217 2.22 0.03441 
Heterogeneous nuclear 










3.4 Pathway and network analyses 
The panel of genes significantly correlated with resistance or sensitivity (P < 
0.05) to the MEK inhibitor was imported into IPA (Ingenuity Systems, 
http://www.ingenuity.com) to analyze network interactions. Networks of these 
significantly correlated genes were then algorithmically generated on the basis of 
their connectivity. 
Genes with significant changes in expression following hypertension were 
assigned to different canonical signaling pathways and subjected to IPA where 
the resulting 95 DEGs in MCA, 67 DEGs in FC and 59 DEGs in common were 
mapped to networks defined by the IPA database. 
The top network with the highest number of DEGs in MCA is involved in Cell 
Cycle, Connective Tissue Development and Function, Cell Death. There were a 
total of 9 networks mapped from the 67 DEGs found in MCA (Figure 3).The top 
network in FC is involved in Carbohydrate Metabolism, Cell Death, Cellular 
Assembly and Organization with 16 DEGs involved. There were a total of 13 
networks mapped 67 DEGs in FC (Figure 4). There were 9 networks found from 
the common DEGs between MCA and FC (Figure 5). The top network had 16 
DEGs and was functionally involved in Cell Cycle, Cell Death, Cell-To-Cell 



























3.5 Real-Time PCR 
Real-time RT-PCR was used to validate the results of the microarray analysis for 
the selected genes of interest. In total, 16 top DEGs were selected to be detected 
by this method. According to the results (Figure 6), there were 8 genes that were 
verified. PTGDR, PPARA and P450 showed up regulation while Gab3, PRLR, 
Tnfs14, SELL and Lass3 showed down regulation. 
 
 
Fig 6. Real-Time PCR results. Data are plotted as mean ± S.D. and analyzed by 






3.6 Western Blot 
The antibodies to Gab3, LASS3, Tnfsf14, PTGDR, SELL, PPARA, PRLR and 
P450 detected bands at around 75kDa, 46kDa, 25kDa, 43kDa, 81kDa 55kDa, 
100kDa and 56kDa respectively, consistent with the expected molecular weights 
of these proteins. The antibody to β-actin reacted against a band at 42 kDa. 
Significant difference in the density ratios of P450, PPARA, LASS3 and 
PTGDR to β-actin bands was observed in western blots of the 2K1C rabbits, 
compared to the control rabbits at this time (Fig 7a, b). Among the four genes 
with significant change, P450, PPARA and PTGDR show upregulation to the 
control group while LASS3 show downregulating function. All of them are in 
accordance with the results from the Real Time PCR. Besides, two of the above 
genes, Gab3 and Tnfsf14, do have significant difference between the treatment 
group and the control group, however, both of them expressed higher than the 
control samples, which is just the opposite from the previous analysis.  
Contrastively, although PRLR and SELL, the last two genes had the same trend 
of decrease according to former results, their regulation ability was not as strong 





 Fig 7. Western blot analysis of Gab3, Tnfsf14, Lass3, PTGDR, PPARA and 
P450 in comparison to Beta Actin. Sample size is 25μl. Data are plotted as mean 

































































This study was carried out to examine the global gene expression in the rabbit 
MCA and FC upon consumption of high level of blood pressure as well as to 
further elucidate the pathways that might be important towards the contribution 
of arteriosclerosis. An initial step in the process of arteriosclerosis is endothelial 
dysfunction with endothelial macrophage adhesion, followed by their infiltration 
into the blood vessel wall. Endothelial dysfunction reduces nitric oxide (NO) 
production and leads to vasoconstriction. 
Numbers of previous studies proved endothelial dysfunction is thought to be a 
key event in the development of atherosclerosis and predates clinically obvious 
vascular pathology (Abrams et al, 1997, Adams et al 1999). The reason is that 
endothelial dysfunction has strong relationship with reduced anticoagulant 
properties as well as increased adhesion molecule expression, chemokine and 
other cytokine release, and reactive oxygen species production from the 
endothelium, all of which play important roles in the development of 
atherosclerosis. In fact, endothelial dysfunction influenced significantly in 
predicting vascular events including stroke and heart attacks (Poredos et al.2006). 
Endothelial function testing may have great potential prognostic value for the 
detection of cardiovascular disease, but because of high price and difficult 
operation, currently the available tests are not wide accepted in clinical use. 
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Microarray analysis of the brain was used to identify differential gene expression 
in vessels and brain tissue from the rabbits at risk of hypertension. Although the 
weight changes and serum cholesterol level between treated and control groups 
were not significantly different, consumption of the 2-kidney, 1-clip Goldblatt 
hypertension model produced a marked increase in mean arterial pressure levels. 
Acording to the primary scanning by Microarray results, we can find out some of 
them were repeatedly mentioned their importance by other related study. The 
canonical pathways analyses show PPARA is regulated by arachidonic acid, 
indomethacin and is found in the cytoplasm and nucleus of the cell. It appears to 
have roles in diseases such as hyperlipidemia, diabetes mellitus, 
hypercholesterolemia, Alzheimer's disease, carotid artery disease, coronary 
artery disease, atherosclerosis and hypertension. Previous study proved that 
PPARA is a transcription factor and a major regulator of lipid metabolism in the 
liver. PPARA is activated under nutrient-deficient conditions and is necessary 
for the process of ketogenesis, a key adaptive response to prolonged fasting 
(Kersten et al, 1999). Activation of PPARA promotes uptake, utilization, and 
catabolism of fatty acids by upregulation of genes involved in fatty acid transport 
and peroxisomal and mitochondrial fatty acid β-oxidation. PPARA is primarily 
activated through ligand binding. Synthetic ligands include the fibrate drugs, 
which are used to treat hyperlipidemia. An endogenous ligand has been 
identified as the phosphatidylcholine species 1-palmitoyl-2-oleoyl-sn-glycerol-3-
phosphocholine (Chakravarthy et al, 2009). Endogenous activation of PPARA is 
dependent on the presence of fatty acid synthase.  
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P450 is located on the cell surface, Cytoplasm and its role in the cell involves 
respiration. It has been found to be associated with diseases such as drug toxicity, 
fibrosis, paralysis, hydrocephalus, hypertrophy, weight gain, and infarction.  
TNF is an important gene that is regulated by several other genes, including 
lipopolysaccharide. It is found to be involved in several diseases and has several 
cellular functions and roles. This gene encodes a multifunctional 
proinflammatory cytokine that belongs to the tumor necrosis factor (TNF) 
superfamily. This cytokine is mainly secreted by macrophages. It can bind to, 
and thus functions through its receptors TNFRSF1A/TNFR1 and 
TNFRSF1B/TNFBR. This cytokine is involved in the regulation of a wide 
spectrum of biological processes including cell proliferation, differentiation, 
apoptosis, lipid metabolism, and coagulation. This cytokine has been implicated 
in a variety of diseases, including autoimmune diseases, insulin resistance, and 
cancer. Knockout studies in mice also suggested the neuroprotective function of 
this cytokine (Nedospasov et al, 1986). 
The protein encoded IL9 is a cytokine receptor that specifically mediates the 
biological effects of this gene. The functional IL9 receptor complex requires this 
protein as well as the interleukin 2 receptor, gamma (IL2RG), a common gamma 
subunit shared by the receptors of many different cytokines (Romero et al, 2010). 
The ligand binding of this receptor leads to the activation of various JAK kinases 
and STAT proteins, which connect to different biologic responses. This gene is 
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located at the pseudoautosomal regions of X and Y chromosomes. Genetic 
studies suggested an association of this gene with the development of asthma.  
ASTN2 is another gene related to brain function. It encodes a protein that is 
expressed in the brain and may function in neuronal migration, based on 
functional studies of the related astrotactin 1 gene in human and mouse. A 
deletion at this locus has been associated with schizophrenia. Multiple transcript 
variants encoding different proteins have been found for this locus 
In the FC, P450 was found to have the highest fold change (>24). This gene 
encodes a member of the cytochrome P450 superfamily of enzymes. The 
cytochrome P450 proteins are monooxygenases which catalyze many reactions 
involved in drug metabolism and synthesis of cholesterol, steroids and other 
lipids. The protein encoded by this gene localizes to the endoplasmic reticulum 
and its expression is induced by some polycyclic aromatic hydrocarbons (PAHs), 
some of which are found in cigarette smoke. The enzyme's endogenous substrate 
is unknown; however, it is able to metabolize some PAHs to carcinogenic 
intermediates. Other xenobiotic substrates for this enzyme include caffeine, 
aflatoxin B1, and acetaminophen. The transcript from this gene contains four 
Alu sequences flanked by direct repeats in the 3' untranslated region. In a system 
of purified components, human CYP1A2 protein increases metabolism of 
arachidonic acid (Choudhary et al. 2004) 
Other genes that were found in FC were SELL and PTGDR. SELL encodes a 
cell surface adhesion molecule that belongs to a family of adhesion/homing 
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receptors. The encoded protein contains a C-type lectin-like domain, a calcium-
binding epidermal growth factor-like domain, and two short complement-like 
repeats. The gene product is required for binding and subsequent rolling of 
leucocytes on endothelial cells, facilitating their migration into secondary 
lymphoid organs and inflammation sites. Single-nucleotide polymorphisms in 
this gene have been associated with various diseases including immunoglobulin 
a nephropathy. Selectin protein(s) is involved in adherence of platelets and 
endothelial cells that is increased by inflammation in organism (Juliano 2002). 
On the other hand, PTGDR is a G-protein-coupled receptor. It has been shown to 
function as a prostanoid DP receptor. The activity of this receptor is mainly 
mediated by G-S proteins that stimulate adenylate cyclase resulting in an 
elevation of intracellular cAMP and Ca2+. Knockout studies in mice suggest that 
the ligand of this receptor, prostaglandin D2 (PGD2), functions as a mast cell-
derived mediator to trigger asthmatic responses. It also involved in eicosanoid 
signalling pathway. 
Genes in common between MCA and FC were Gab3. This gene is a member of 
the GRB2-associated binding protein gene family. These proteins are 
scaffolding/docking proteins that are involved in several growth factor and 
cytokine signalling pathways, and they contain a pleckstrin homology domain, 
and bind SHP2 tyrosine phosphatase and GRB2 adapter protein. The protein 
encoded by this gene facilitates macrophage differentiation (Wolf et al. 2002). 
Two transcript variants encoding different isoforms have been found for this 
gene. Disease: AD (Li et al. 2008). Besides, Tnfs14 was also found with 
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common regulation both in MCA and FC. It is production and release of 
chemokines, cytokines (Blumberg et al. 2010, McInnes & Schett 2007). MMP 
(McInnes & Schett 2007),Found in neutrophil (Moore et al. 2001), macrophages 
(Green et al. 1994), endothelial cells. It has increase activation of endothelial 
cells (Hopkins 2007) and disruption of endothelial cells (Chen & Cosgriff 2000). 
After detailed analysis by IPA system, all the selective genes were grouped by 
networks and locations. The gene maps clearly demonstrate the gene relation 
within the same network. They may have similar function or related to the same 
target or receptors. Here we picked up FC Network 1 map as the main study 
target, which include most of our interest genes such as Tnfsf14, PRLR, SELL, 
PTGDR and Gab3. Especially PPARA which standing in the center place of the 
network and tightly linked with many other functional genes, it might play an 
irreplaceable position and probably had strong influence on our target disease. 
The fact not only from the Real-Time PCR analysis but also the western blot 
detection both proved PPARA do has such a powerful influence: it keeps the top 
position of significance, followed by P450, PTGDR and other important genes, 
which means further research may pay more attention on the interaction between 
these groups of genes. 
Since all theses involved genes are strongly related with stroke and other 
cardiovascular disease, or have correlative physiological function according to 
previous research, we can draw a conclusion that these genes will form a 
significant part in the formation of development of the diseases which are 
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mentioned above. The results from this study may support and provide evidences 
for the future research in exploring the principle of the stroke related diseases 
and contribute to discover the treatments for the stroke and hypertension patients.  
 
4.2 Limitations and future study 
The limitation of numbers of the animals and obvious physiological difference 
between individuals compromised of the data we collected from the samples. For 
example, the reproducibility one experimental animals is questionable by using 
the 2K1C method. For future study, an enlarged database is necessary to enhance 
the reliability of the results. If possible, more various models should be applied 
such as 1K1C method to form a meaningful comparison. 
For the 1K1C model itself, it was first developed in 1934, which is quite a long 
time before today. Although it is a traditional and standard model, it still can be 
improved. Many articles reported that they combine the hypertension model 
together with high cholesterol food treatments, in order to discover the 
connections between hypertension and hyperlipidemia, which are always tightly 
related in clinical cases. And it is also our future plan for the next step.  
During the step by step analysis, sometimes the same gene shows totally 
opposite direction of change. Take Gab3 as an example, it was upregulated in 
both microarray analysis and western blotting, however downregulated in RT-
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PCR analysis. This situation may be caused by the low accuracy of large amount 
detection, the quality of the probes and antibodies, or the status of the samples.  
These can be avoided in the future. It is also conceivable that some of the genes 
have different expression according to changeable environment and locations. 
The possible presence of different splice forms or post-translational 
modifications of the protein targets may influence the discrepancy between 
observations from different methods. All of these can be very promising research 
direction to continue and develop this topic. Besides, there are still huge amount 
of gene selected by microarray, here we only picked 16 as our interest genes and 
more are waiting for the future project. 
After all, there are more methods for more accurate detection could be applied in 
further research based on the results we got till now. Such as 
Immunohistochemistry and Electron Microscopy are the next step for discover 
more detailed information from the primary scanning results. Similar methods 








This study applied microarray to detect the expression profile of various genes in 
the frontal cortex and middle cerebral artery that are involved and regulated in 
hypertension through the 2-kidney, 1-clip Goldblatt hypertension model.  Genes 
were filtered step by step and subjected to the Ingenuity Pathway Analysis. 
Finally, four genes: PPARA, P450, PTGDR and LASS3 were selected as the 
most significant change after treatment. Most of them may have strong 
relationship based on the gene map and deeply involved in the target diseases. 
Further study around these genes may lead to a better understanding on the role 
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